Takeda Pharmaceutical (TKPHF) Receivables (2017 - 2026)

Takeda Pharmaceutical's Receivables history runs 10 years deep, the most recent figure standing at $5.4 billion for Q1 2026.

• In Q1 2026, Receivables rose 7.02% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $5.4 billion (up 7.02% YoY), while the FY2026 annual figure was $5.6 billion, up 11.32% from the prior year.
• Receivables was $5.4 billion for Q1 2026 at Takeda Pharmaceutical, up from $4.8 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $5.9 billion in Q2 2022 to a low of $529.0 million in Q1 2023.
• Historically, Receivables has averaged $4.5 billion across 5 years, with a median of $4.9 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Receivables sank 92.65% in 2022, then soared 824.04% in 2024.
• A 5-year view of Receivables shows it stood at $5.0 billion in 2022, then declined by 3.22% to $4.8 billion in 2023, then dropped by 3.42% to $4.7 billion in 2024, then grew by 2.26% to $4.8 billion in 2025, then grew by 12.5% to $5.4 billion in 2026.
• The last three Receivables figures came in at $5.4 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.